TruGraf Liver Gene Expression Serial Test

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Sep 27, 2023

Keywords

ClinConnect Summary

Study Abstract Following liver transplantation, organ recipients require long-term immunosuppression therapy along with frequent surveillance of the transplanted graft for indications of rejection, injury or failure. Long-term death rates in liver transplantation are more often attributable to long-term intake of immunosuppression medications than to liver graft dysfunction. Excessive immunosuppression can lead to declining kidney function, recurrent infections and other issues especially in the aging recipient population while suboptimal immunosuppression can lead to allograft injury, reje...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Recipients ≥18 years of age
• • Currently waitlisted for liver transplant or recipient of liver transplant within the last 30 days
• • Primary indication for transplant due to autoimmune hepatitis (AIH) - Primary Biliary Cirrhosis (PBC) or Primary Sclerosing Cholangitis (PSC) etiologies
• • First time, single-organ liver transplant recipient
• • Willing and able to undergo protocol required TruGraf serial blood draws
• Exclusion Criteria:
• • Recipient \<18 years of age
• • Recipients of multi-organ or repeat transplantation
• • Grafts from donors with HIV
• • Grafts from donors with viremic Hepatitis A, B, C
• • Inability to meet study requirements